What Is SLU-PP-332? SLU-PP-332 is a synthetic small molecule compound developed at Washington University in St. Louis — the “SLU” prefix in its name reflects this institutional origin.
Semaglutide is the established GLP-1 agonist behind Ozempic. Survodutide targets both GLP-1 and glucagon receptors, with Phase 2 data showing potentially greater fat loss. A research comparison of both compounds.
Cluster headaches are among the most painful conditions known. Early research explores how peptides like BPC-157 and Selank may influence the neurological and inflammatory pathways involved in these severe headache attacks.
Migraine research has explored BPC-157 for nitric oxide modulation, Selank for stress-axis effects, and Semax for cortical mechanisms. Here’s what preclinical data shows about peptides and migraine biology.
GHK-Cu and retinol are two of the most evidence-backed skin rejuvenation ingredients. Both stimulate collagen but through different mechanisms. This research comparison covers tolerability, efficacy, and whether they can be combined.
Research has explored Selank, Semax, and DSIP for seizure-related mechanisms including GABAergic modulation, post-seizure neuroprotection, and neuroinflammation reduction. Here’s what preclinical data shows.
Huntington’s disease has no disease-modifying treatment. Research explores Semax, Selank, and Cerebrolysin for their neuroprotective and anti-inflammatory properties in HD-relevant models.
What Is Pinealon? Pinealon is a synthetic tripeptide with the amino acid sequence Glu-Asp-Arg (glutamic acid–aspartic acid–arginine), commonly abbreviated as EDR.
Survodutide represents a distinctive approach in the evolving landscape of multi-receptor metabolic peptides.
GHK-Cu is one of the most studied skin peptides. Research shows cellular changes begin within days, but meaningful measurable skin improvements typically emerge over 4–12 weeks. Here’s the full timeline.
